Filing Overview
Arcturus Therapeutics Holdings Inc. filed a Form 8-K dated February 9, 2022, with the report signed on February 11, 2022. The filing reports a management transition under Item 5.02.
Business Context and Reporting Period
Arcturus is a Delaware corporation headquartered in San Diego, California, with common stock trading on Nasdaq under the symbol ARCT. The filing does not provide quarterly or annual financial results.
Management Changes
- Effective February 14, 2022, Dr. Steve Hughes stepped down as Chief Medical Officer.
- Dr. Hughes will continue supporting the company and its programs in the immediate future as Strategic Clinical Advisor.
- Dr. Kelly Lindert, previously Senior Vice President and Head of Vaccines, will assume the role of Chief Development Officer, Vaccines.
Financial Metrics and Capital Structure
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Outlook, Risks, and Unusual Items
The filing does not state a revised financial outlook or identify specific risks or contingencies. The principal disclosed item is the transition in clinical and vaccine-development leadership.
Investor Verification Points
- Verify the effective date of Dr. Hughes’s departure from the Chief Medical Officer role: February 14, 2022.
- Confirm Dr. Hughes’s continuing role as Strategic Clinical Advisor.
- Confirm Dr. Lindert’s appointment as Chief Development Officer, Vaccines, and assess any subsequent disclosures regarding responsibilities or execution of vaccine programs.